Bioreactor technologies to support liver function in vitro
Name
Griffith_Bioreactor technologies.pdf
Size
3.39 MB
Format
Adobe PDF
Checksum (MD5)
bd21a04e4b2f915e2087bebf7b2ceb12
Author(s)
Neiman, Jaclyn A. Shepard
Hughes, David J.
Griffith, Linda G.
Ebrahimkhani, Mohammad Reza
Raredon, Micha Sam Brickman
Date Issued
March 2014
Journal
Advanced Drug Delivery Reviews
Publisher
Elsevier
Citation
Ebrahimkhani, Mohammad R., Jaclyn A. Shepard Neiman, Micha Sam B. Raredon, David J. Hughes, and Linda G. Griffith. “Bioreactor Technologies to Support Liver Function in Vitro.” Advanced Drug Delivery Reviews 69–70 (April 2014): 132–157.
Version
Author's final manuscript
Abstract
Liver is a central nexus integrating metabolic and immunologic homeostasis in the human body, and the direct or indirect target of most molecular therapeutics. A wide spectrum of therapeutic and technological needs drives efforts to capture liver physiology and pathophysiology in vitro, ranging from prediction of metabolism and toxicity of small molecule drugs, to understanding off-target effects of proteins, nucleic acid therapies, and targeted therapeutics, to serving as disease models for drug development. Here we provide perspective on the evolving landscape of bioreactor-based models to meet old and new challenges in drug discovery and development, emphasizing design challenges in maintaining long-term liver-specific function and how emerging technologies in biomaterials and microdevices are providing new experimental models.
MIT Department
Massachusetts Institute of Technology. Center for Gynepathology Research
Massachusetts Institute of Technology. Department of Biological Engineering
Massachusetts Institute of Technology. Department of Chemical Engineering
Massachusetts Institute of Technology. Department of Materials Science and Engineering
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.addr.2014.02.011
